| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BCL1; PRAD1; U21B31; D11S287E |
| Entrez GeneID | 595 |
| clone | 1F7F5 |
| WB Predicted band size | 33.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human CCND1 (AA: 1-295) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CCND1抗体的3篇参考文献示例(文献名称、作者及摘要内容概括)：
---
1. **文献名称**: "Cyclin D1 as a therapeutic target in cancer"
**作者**: Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL
**摘要**: 该研究探讨了CCND1在多种癌症中的过表达机制及其作为治疗靶点的潜力。作者使用特异性CCND1抗体进行免疫组化分析，发现其在乳腺癌和套细胞淋巴瘤中异常高表达，并与预后不良相关。
2. **文献名称**: "Frequent amplification of chromosomal region 11q13 in mantle cell lymphoma detected by comparative genomic hybridization"
**作者**: Bea S, Ribas M, Hernández JM, et al.
**摘要**: 研究通过比较基因组杂交技术发现套细胞淋巴瘤中11q13染色体区域(含CCND1基因)的频繁扩增，并利用CCND1抗体进行Western blot和免疫荧光验证，证实了蛋白水平的过表达与基因扩增直接相关。
3. **文献名称**: "Immunohistochemical analysis of cyclin D1 in parathyroid tumors"
**作者**: Vasef MA, Brynes RK, Sturm M, et al.
**摘要**: 该文献通过免疫组化方法(使用特异性CCND1单克隆抗体)分析甲状旁腺肿瘤中CCND1的表达，发现其在恶性病变中的高表达率显著高于良性腺瘤，提示其可作为鉴别诊断的生物标志物。
---
**注**：以上文献信息为示例，实际引用时需核对具体来源及准确性。如需近期文献，建议通过PubMed或Web of Science检索关键词“CCND1 antibody”+“应用场景”(如癌症类型或实验方法)获取最新研究。
The CCND1 antibody is a crucial tool in molecular and cancer research, targeting cyclin D1. a key regulator of the cell cycle. Cyclin D1 (encoded by the *CCND1* gene) belongs to the cyclin protein family and plays a pivotal role in driving the G1-to-S phase transition by forming complexes with cyclin-dependent kinases (CDKs), primarily CDK4/6. These complexes phosphorylate retinoblastoma (Rb) protein, releasing transcription factors that promote cell cycle progression. Dysregulation of CCND1. often due to gene amplification, chromosomal translocation, or transcriptional upregulation, is implicated in various cancers, including breast cancer, mantle cell lymphoma, and multiple myeloma, making it a biomarker of oncogenic activity.
CCND1 antibodies are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein expression levels in tissues or cell lines. Researchers utilize these antibodies to study cell cycle abnormalities, tumorigenesis mechanisms, and therapeutic responses, particularly in cancers with CCND1 overexpression. Additionally, CCND1 antibodies aid in evaluating the efficacy of CDK4/6 inhibitors, a class of targeted cancer therapies. Their specificity varies depending on epitope targets (e.g., N-terminal or C-terminal regions), and validation for intended applications is critical. Understanding CCND1's role in cellular proliferation and its association with poor prognosis underscores the antibody's relevance in both basic research and clinical diagnostics.
×
